Gasporox Q1 2024: Just as expected - Redeye

Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA seven consecutive quarters in a row, thus trending towards profitability. Sales were driven by VialArch, GPX1500 Vial, and after-sales. Gasporox, with SEK10.4m in cash and SEK12.8m in working capital, is financially stable but faces risks with a convertible loan that could be settled in cash if shares fall below SEK8.5. However, significant stakeholders might opt to increase their shares, and a non-specific contingency plan exists for such settlements.

Länk till analysen i sin helhet: https://www.redeye.se/research/997065/gasporox-q1-2024-just-as-expected?utm_source=finwire&utm_medium=RSS